Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Caribou Biosciences, Inc. (CRBU)  
$1.26 0.00 (0.00%) as of 4:30 Fri 6/27


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 88,430,000
Market Cap: 111.42(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.7331 - $2.79
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Caribou Biosciences is a clinical-stage genome-editing biopharmaceutical company focused on developing transformative Clustered Regularly Interspaced Short Palindromic Repeats therapies for patients with devastating diseases. Co.'s primary product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cell therapy with programmed cell death protein 1 removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. CB-012 is Co.'s allogeneic armored CAR-T cell product candidate targeting CD371, which is in preclinical development for the treatment of relapsed or refractory acute myeloid leukemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 37,360 37,360 37,360
Total Buy Value $0 $45,051 $45,051 $45,051
Total People Bought 0 2 2 2
Total Buy Transactions 0 2 2 2
Total Shares Sold 0 10,692 10,692 10,692
Total Sell Value $0 $14,433 $14,433 $14,433
Total People Sold 0 3 3 3
Total Sell Transactions 0 3 3 3
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 45
  Page 1 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Haurwitz Rachel E. President and CEO   •       •      –    2025-03-14 4 B $1.02 $20,400 I/I 20,000 3,369,395 2.58 25%     
   Mcclung Barbara G Chief Legal Officer   •       –      –    2025-02-21 4 AS $1.35 $4,811 D/D (3,564) 443,502 -4%     
   Kanner Steven Chief Scientific Officer   •       –      –    2025-02-21 4 AS $1.35 $4,811 D/D (3,564) 431,556 -4%     
   Khan Ruhi Ahmad Chief Business Officer   •       –      –    2025-02-21 4 AS $1.35 $4,811 D/D (3,564) 66,936 -4%     
   Mcclung Barbara G Chief Legal Officer   •       –      –    2025-02-20 4 A $0.00 $0 D/D 37,500 447,066     -
   Kanner Steven Chief Scientific Officer   •       –      –    2025-02-20 4 A $0.00 $0 D/D 37,500 435,120     -
   Kelly Timothy P Chief Technology Officer   •       –      –    2025-02-20 4 A $0.00 $0 D/D 37,500 37,500     -
   Khan Ruhi Ahmad Chief Business Officer   •       –      –    2025-02-20 4 A $0.00 $0 D/D 37,500 70,500     -
   Haurwitz Rachel E. President and CEO   •       •      –    2025-02-20 4 A $0.00 $0 D/D 136,750 295,450     -
   Albertson Tina M. Chief Medical Officer   •       –      –    2025-02-20 4 A $0.00 $0 D/D 14,589 14,589     -
   Ryali Sriram Chief Financial Officer   •       –      –    2025-01-29 4 B $1.42 $24,651 D/D 17,360 17,360 2.74 -5%     
   Fischesser Ryan VP of Finance and Controller   •       –      –    2024-11-20 4 A $0.00 $0 D/D 25,000 118,854     -
   Fischesser Ryan VP of Finance and ControllerOf   •       –      –    2024-09-27 3 IO $0.00 $0 D/D 0 93,854 -32%     
   Obyrne Jason Chief Financial Officer   •       –      –    2024-02-20 4 A $0.00 $0 D/D 33,000 59,224     -
   Khan Ruhi Ahmad Chief Business Officer   •       –      –    2024-02-20 4 A $0.00 $0 D/D 33,000 33,000     -
   Mcclung Barbara G Chief Legal Officer   •       –      –    2024-02-20 4 A $0.00 $0 D/D 33,000 409,566     -
   Kanner Steven Chief Scientific Officer   •       –      –    2024-02-20 4 A $0.00 $0 D/D 33,000 387,037     -
   Haurwitz Rachel E. President and CEO   •       •      –    2024-02-20 4 A $0.00 $0 D/D 118,700 158,700     -
   Kanner Steven Chief Scientific Officer   •       –      –    2024-02-06 4 OE $2.69 $82,252 D/D 30,577 354,037     -
   Haurwitz Rachel E. President and CEO   •       •      –    2023-06-08 4 OE $2.96 $29,600 D/D 10,000 40,000     -
   Haurwitz Rachel E. President and CEO   •       •      –    2023-03-20 4 OE $2.96 $29,600 D/D 10,000 30,000     -
   Rizvi Syed Ali-Aamir Chief Medical Officer   •       –      –    2023-01-19 4 S $6.31 $35,506 D/D (5,627) 59,373 31%     
   Kanner Steven Chief Scientific Officer   •       –      –    2022-12-02 4 OE $2.69 $57,569 D/D 21,401 323,460     -
   Fischesser Ryan VP of Finance and Controller   •       –      –    2022-10-06 4 OE $2.69 $19,305 D/D 5,678 116,044     -
   Fischesser Ryan VP of Finance and Controller   •       –      –    2022-10-06 4 S $10.80 $107,958 D/D (10,000) 110,366 37%     
  45 Records found
  1  2   
  Page 1 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us